Form 4: Arrowhead CMO James Hamilton Sells 10,000 Shares

Arrowhead Pharmaceuticals Chief Medical Officer James C. Hamilton sold 10,000 shares of common stock via a 10b5-1 trading plan.

Summary

• Chief Medical Officer James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals common stock.
• The transaction occurred on April 23, 2026, at a weighted average price of $75.00 per share.
• The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan.
• Following the transaction, the reporting person retains beneficial ownership of 226,958 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 arrangement, which is standard practice for executive financial planning.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The transaction represents a reduction in the direct equity stake held by a key member of the executive leadership team.

Risks

• Executive stock sales can sometimes be perceived negatively by the market as a signal of management's view on the company's near-term valuation.

Future Outlook

No specific forward-looking guidance regarding company operations or financial performance was provided in this filing.

Management Comments

• The reporting person has committed to providing full information regarding the number of shares sold at each separate price within the reported range upon request.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are common in the biotechnology sector and are typically viewed as routine liquidity events rather than indicators of fundamental business health.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is the industry standard for corporate officers to manage personal equity holdings while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• No future corporate actions or milestones were disclosed in this filing.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, Insider Trading, Form 4, Biotech, Executive Compensation